| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 99,24 | 99,88 | 09:09 | |
| 99,24 | 99,86 | 09:09 |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 115,00 | 67 | |||
| 110,00 | 260 | |||
| 100,24 | 5 | |||
| 100,20 | 5 | |||
| 100,16 | 15 | |||
| 99,91 | 897 | |||
| 99,88 | 75 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/6mk.htm [/URL] | ||||
| 75 | 99,38 | |||
| 897 | 99,37 | |||
| 15 | 99,08 | |||
| 5 | 99,06 | |||
| 5 | 99,04 | |||
| 150 | 96,46 | |||
| 150 | 96,44 | |||
| 150 | 96,42 | |||
| 75 | 79,50 | |||
| 1.094 | 0,000 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 2.616 | 0,506 | 1.324 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 20.04.2026 | 15:35:47 | 100,28 | 1 |
| 20.04.2026 | 15:35:47 | 100,28 | 200 |
| 20.04.2026 | 15:33:36 | 100,90 | 248 |
| 20.04.2026 | 15:33:36 | 100,90 | 200 |
| 20.04.2026 | 15:33:28 | 100,90 | 142 |
| 20.04.2026 | 15:03:08 | 100,90 | 100 |
| 20.04.2026 | 11:23:52 | 100,82 | 39 |
| 20.04.2026 | 10:56:23 | 99,91 | 10 |
| 20.04.2026 | 10:44:38 | 99,89 | 8 |
| 20.04.2026 | 10:42:19 | 99,73 | 3 |
| 20.04.2026 | 10:38:48 | 99,89 | 1 |
| 20.04.2026 | 09:54:17 | 100,38 | 5 |
| 20.04.2026 | 09:54:17 | 100,38 | 1 |
| 20.04.2026 | 09:50:44 | 100,28 | 2 |
| 20.04.2026 | 09:40:18 | 100,22 | 30 |
| 20.04.2026 | 09:10:33 | 100,46 | 110 |
| 20.04.2026 | 09:10:33 | 100,86 | 62 |
| 20.04.2026 | 09:04:44 | 101,24 | 1 |
| 20.04.2026 | 09:04:42 | 101,24 | 2 |
| 20.04.2026 | 09:04:42 | 100,94 | 71 |
| Tagesumsatz Xetra | - | 0 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| MERCK & CO Aktie jetzt für 0€ handeln | |||||
| 04:26 | Merck Wins EU Approval for ENFLONSIA to Protect Infants from RSV | 2 | Insider Monkey | ||
| Mo | UBS reiterates Merck stock rating on pipeline strength | 6 | Investing.com | ||
| Mo | AACR 2026: Revolution's next prospect, Merck's reveal and a lung cancer battle | 7 | BioPharma Dive | ||
| Mo | Astellas, Pfizer Say FDA Grants Priority Review To SBLA For PADCEV Plus Keytruda | 271 | AFX News | TOKYO (dpa-AFX) - Astellas Pharma Inc. (ALPMY) and Pfizer Inc. (PFE) on Monday said the U.S. Food and Drug Administration has granted Priority Review for a supplemental Biologics License Application... ► Artikel lesen | |
| Mo | Vaginal Drug Delivery Had A Funding Problem-Merck Changed That | 2 | Forbes |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| Mo | Jaguar Health, Inc.: Jaguar Health Reports Approval of All Proposals at April 2026 Special Meeting of Stockholders | ACCESS Newswire | SAN FRANCISCO, CA / ACCESS Newswire / April 20, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the voting results of the Company's Special Meeting of Stockholders... ► Artikel lesen | |
| Mo | Novo Nordisk Aktie: Etavopivat überzeugt - so reagieren zwei Analysten | 4investors | Positive Studiendaten für Novo Nordisk: Das Präparat Etavopivat zur Behandlung der Sichelzellkrankheit hat die Phase-III-Studie erfolgreich abgeschlossen. Zwei Investmentbanken sehen in den Ergebnissen... ► Artikel lesen | |
| 06:54 | JPMORGAN stuft BAYER AG auf 'Overweight' | dpa-AFX-Analyser | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Bayer mit einem Kursziel von 50 Euro auf "Overweight" belassen. Analyst Richard Vosser erwartet das operative Ergebnis (Ebitda)... ► Artikel lesen | |
| Mo | Lilly Agrees To Acquire Kelonia Therapeutics For Up To $7 Bln | AFX News | INDIANAPOLIS (dpa-AFX) - Eli Lilly and Company (LLY), a biotech company, Monday announced that it has agreed to acquire Kelonia Therapeutics, Inc. a clinical biotechnology company pioneering... ► Artikel lesen | |
| Mo | ALK Abello: ALK announces successful outcome of phase 2 trial with its tablet for treatment of peanut allergy demonstrating early onset of efficacy | GlobeNewswire (Europe) | Inside Information The ALLIANCE phase 2 trial demonstrated proof-of-concept after only 6 months of maintenance treatment in a broad patient population comprising both children and adults.Clear dose-dependent... ► Artikel lesen |